BeOne Medicines reports positive results from phase 3 MANGROVE study of Brukinsa in frontline mantle cell lymphoma: San Carlos, California Thursday, July 2, 2026, 10:00 Hrs [IST] ...

Independent review–assessed PFS met the primary endpoint with zanubrutinib-rituximab versus bendamustine-rituximab (HR, 0.57; P<.0001), supporting a chemotherapy-free frontline strategy in MCL.

Patients with newly diagnosed mantle cell lymphoma (MCL) could avoid chemotherapy with a regimen based on BeOne Medicines' ...

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the Phase 3 MANGROVE study (BGB-3111-306; NCT04002297) evaluating ...

A Brukinsa regimen has delivered a large progression-free survival (PFS) benefit in what BeOne Medicines called a “new ...

Femi Aremu, PharmD, is a professional pharmacist with experience in clinical and community pharmacy. He currently practices in Chicago, Illinois. An iron infusion can quickly increase iron levels if ...